SEPN insider buying and SEC filings, explained
Septerna, Inc. · CIK 1984086
Tracked: Forms 3/4/5, 8-K, NT · All filings on sec.gov
Insider activity in the last 12 months
Bought
$0
Insiders who bought
0
Sold (not marked 10b5-1)
$63.5M
Planned sales (10b5-1)
$5.3M
Insider purchases and sales, last 12 months
| Traded | Type | What was filed | Source |
|---|---|---|---|
| Oct 15, 2026 | Planned (10b5-1) | Elizabeth Bhatt (President / COO) sold 4,000 shares at about $37.41 ($150K), marked as a 10b5-1 plan trade. Holdings down 2% to 174,209 shares. | SEC filing Filed Oct 19, 2026, 7:00 PM ET |
| Sep 1, 2026 | Planned (10b5-1) | Daniel D. Long (SVP, Drug Discovery) sold 3,333 shares at about $37.83 ($126K), marked as a 10b5-1 plan trade. Holdings down 3% to 96,412 shares. | SEC filing Filed Sep 3, 2026 |
| Aug 12, 2026 | Sale | Peter Kolchinsky (Director and 10% owner) sold 1,493,000 shares indirectly at $42.50 ($63.5M). Indirect holdings down 67% to 725,443 shares. Not marked as a 10b5-1 plan trade. Filed jointly with 4 other reporting owners. | SEC filing Filed Aug 14, 2026 |
| Aug 11, 2026 | Planned (10b5-1) | Elizabeth Bhatt (President / COO) sold 25,000 shares at $44.00 ($1.1M), marked as a 10b5-1 plan trade. Holdings down 13% to 174,209 shares. | SEC filing Filed Aug 13, 2026 |
| Aug 3, 2026 | Planned (10b5-1) | Daniel D. Long (SVP, Drug Discovery) sold 3,334 shares at about $34.47 ($115K), marked as a 10b5-1 plan trade. Holdings down 3% to 96,412 shares. | SEC filing Filed Aug 5, 2026 |
| Jul 15, 2026 | Planned (10b5-1) | Elizabeth Bhatt (President / COO) sold 4,000 shares at about $33.99 ($136K), marked as a 10b5-1 plan trade. Holdings down 2% to 174,209 shares. | SEC filing Filed Jul 17, 2026 |
| Jul 1, 2026 | Planned (10b5-1) | Daniel D. Long (SVP, Drug Discovery) sold 3,333 shares at about $34.36 ($115K), marked as a 10b5-1 plan trade. Holdings down 3% to 96,412 shares. | SEC filing Filed Jul 2, 2026 |
| Jun 29, 2026 | Planned (10b5-1) | Samira Shaikhly (Chief People Officer) sold 2,178 shares at $35.18 ($77K), marked as a 10b5-1 plan trade. Holdings down 73% to 793 shares. | SEC filing Filed Jun 30, 2026 |
| Jun 22, 2026 | Planned (10b5-1) | Daniel D. Long (SVP, Drug Discovery) sold 15,000 shares at about $35.51 ($533K), marked as a 10b5-1 plan trade. Holdings down 13% to 96,412 shares. | SEC filing Filed Jun 24, 2026 |
| Jun 12, 2026 | Planned (10b5-1) | Samira Shaikhly (Chief People Officer) sold 6,250 shares at about $35.08 ($219K), marked as a 10b5-1 plan trade. Holdings down 89% to 793 shares. | SEC filing Filed Jun 16, 2026 |
| Jun 1, 2026 | Planned (10b5-1) | Samira Shaikhly (Chief People Officer) sold 5,935 shares at about $28.92 ($172K), marked as a 10b5-1 plan trade. Holdings down 88% to 793 shares. | SEC filing Filed Jun 3, 2026 |
| May 26, 2026 | Planned (10b5-1) | Samira Shaikhly (Chief People Officer) sold 11,798 shares at about $30.06 ($355K), marked as a 10b5-1 plan trade. Holdings down 94% to 793 shares. | SEC filing Filed May 28, 2026 |
| Apr 15, 2026 | Planned (10b5-1) | Elizabeth Bhatt (President / COO) sold 4,000 shares at about $24.34 ($97K), marked as a 10b5-1 plan trade. Holdings down 2% to 174,209 shares. | SEC filing Filed Apr 17, 2026 |
| Mar 2, 2026 | Planned (10b5-1) | Samira Shaikhly (Chief People Officer) sold 70,453 shares at about $28.10 ($2.0M), marked as a 10b5-1 plan trade. Holdings down 99% to 793 shares. | SEC filing Filed Mar 4, 2026 |
| Feb 18, 2026 | Planned (10b5-1) | Elizabeth Bhatt (President / COO) sold 4,000 shares at about $28.96 ($116K), marked as a 10b5-1 plan trade. Holdings down 2% to 174,209 shares. | SEC filing Filed Feb 20, 2026 |
| Nov 10, 2025 | Sale | Daniel D. Long (SVP, Drug Discovery) sold 3,501 shares at about $18.06 ($63K). Holdings down 4% to 92,911 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Nov 13, 2025 |
32 routine transactions (such as grants, option exercises or tax withholding) are not listed.
Cluster buys
No cluster buys in the last 12 months.
Red flags
No red flags in the last 12 months.
Key events
No key events in the last 12 months.
8-K filings, last 12 months
No 8-K filings in the last 12 months.
Red flags are objective triggers only: the item or form filed, never an opinion.
Follow SEPN in the Insider Ledger app
Get the appA plain-English brief of insider purchases, 8-Ks and red flags at the companies you pick. No account needed.